Codexis Inc. (4QK)
XMUN 
Summary
4QK Chart
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.25 per share a year ago.
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis Inc. (4QK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Codexis Inc. ever had a stock split?
Codexis Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alison Moore CEO | XMUN Exchange | US1920051067 ISIN |
| US Country | 146 Employees | - Last Dividend | - Last Split | 22 Apr 2010 IPO Date |
Overview
Codexis, Inc., established in 2002 and based in Redwood City, California, is a prominent entity in the biotechnology sector, concentrating on the discovery, development, and commercialization of enzymes and other proteins. The organization operates across two primary segments, namely Performance Enzymes and Novel Biotherapeutics. Through its innovative approaches, Codexis caters to a broad spectrum of industries, providing a range of biocatalyst products and services that aim to enhance the efficiency and productivity of manufacturing processes. The company prides itself on its proprietary technology platform, CodeEvolver, which plays a pivotal role in the development and delivery of customized biocatalysts. Codexis stands out in the market with its collaborations, including a notable agreement with Nestlé Health Science for developing treatments aimed at addressing exocrine pancreatic insufficiency. The company’s strategic sales efforts cover the United States and Europe, targeting pharmaceutical manufacturers through its dedicated sales and business development team.
Products and Services
- Biocatalyst Products and Services:
Codexis offers a comprehensive suite of biocatalyst products, along with a range of services including biocatalyst screening and protein engineering. These offerings are designed to support various chemical transformations, thus contributing significantly to the streamlining and enhancement of manufacturing processes across different industries.
- CodeEvolver Technology Platform:
The CodeEvolver platform stands at the core of Codexis' offerings, providing a state-of-the-art method for developing and delivering advanced biocatalysts. This technology is not only crucial for chemical manufacturing but also extends its benefits to molecular biology and the development of in vitro diagnostic enzymes, showcasing the versatile applications of Codexis’ innovations.
- Collaborative Development Projects:
One of Codexis’ strategic moves is its collaboration with Nestlé Health Science for the development of CDX-7108, a biocatalyst aimed at treating exocrine pancreatic insufficiency. This represents the company's commitment to leveraging its proprietary technologies for therapeutic applications, addressing significant unmet medical needs through innovative biotherapeutic solutions.
